CVS Health upgraded by TD Cowen with a new price target
$CVS
Retail-Drug Stores and Proprietary Stores
Consumer Staples
TD Cowen upgraded CVS Health from Hold to Buy and set a new price target of $85.00 from $59.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $55.00 → $75.00 | Market Perform → Outperform | Leerink Partners |
| 2/12/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 1/30/2025 | Hold → Buy | Edward Jones | |
| 12/3/2024 | $66.00 | Hold → Buy | Deutsche Bank |
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo |
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays |
| 10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen |
| 5/30/2024 | $61.00 | Neutral | Robert W. Baird |
WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res
Foundation announces $2 million in new Health Zones funding to support at-risk populations WOONSOCKET, R.I., March 6, 2025 /PRNewswire/ -- The CVS Health® Foundation today announced $2 million in new Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its agency partners, all located in Hartford, Connecticut. This funding will help address critical gaps in the health care and social system for individuals with chronic health conditions by increasing access to comprehensive health care services and resources. "A variety of interconnected fac
WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A
NEW YORK, May 6, 2025 /PRNewswire/ -- One year ago, we established a concentrated position in shares of CVS Health (NYSE:CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan: Board Refreshment – The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director. The entire Board is operating cooperat
First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil
Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously
Cantor Fitzgerald upgraded CVS Health from Neutral to Overweight
Edward Jones upgraded CVS Health from Hold to Buy
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A
First Quarter Financial Highlights Total revenues increased to $94.6 billion, up 7.0% compared to prior yearGAAP diluted EPS of $1.41 and Adjusted EPS of $2.25Generated cash flow from operations of $4.6 billionOperational Highlights CVS Health to exit the individual exchange businessAetna® introduces new solutions to ease the patient and provider experienceCVS Caremark® makes formulary update to improve access to GLP-1 drugs2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83Raised Adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 bil
WOONSOCKET, R.I., April 3, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Thursday, May 1st, 2025, at 8:00 a.m. ET to discuss first quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2024, th
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
10-Q - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)